321 related articles for article (PubMed ID: 30400214)
1. Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces.
Huang H
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400214
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for ligand reception by anaplastic lymphoma kinase.
Li T; Stayrook SE; Tsutsui Y; Zhang J; Wang Y; Li H; Proffitt A; Krimmer SG; Ahmed M; Belliveau O; Walker IX; Mudumbi KC; Suzuki Y; Lax I; Alvarado D; Lemmon MA; Schlessinger J; Klein DE
Nature; 2021 Dec; 600(7887):148-152. PubMed ID: 34819665
[TBL] [Abstract][Full Text] [Related]
3. The ALK receptor in sympathetic neuron development and neuroblastoma.
Janoueix-Lerosey I; Lopez-Delisle L; Delattre O; Rohrer H
Cell Tissue Res; 2018 May; 372(2):325-337. PubMed ID: 29374774
[TBL] [Abstract][Full Text] [Related]
4. The role of anaplastic lymphoma kinase in pediatric cancers.
Takita J
Cancer Sci; 2017 Oct; 108(10):1913-1920. PubMed ID: 28756644
[TBL] [Abstract][Full Text] [Related]
5. Mechanism for the activation of the anaplastic lymphoma kinase receptor.
Reshetnyak AV; Rossi P; Myasnikov AG; Sowaileh M; Mohanty J; Nourse A; Miller DJ; Lax I; Schlessinger J; Kalodimos CG
Nature; 2021 Dec; 600(7887):153-157. PubMed ID: 34819673
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase: Role in cancer and therapy perspective.
Zhao Z; Verma V; Zhang M
Cancer Biol Ther; 2015; 16(12):1691-701. PubMed ID: 26529396
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
Cheng M; Ott GR
Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
[TBL] [Abstract][Full Text] [Related]
8. Dermatan sulphate is an activating ligand of anaplastic lymphoma kinase.
Machino M; Gong Y; Ozaki T; Suzuki Y; Watanabe E; Imagama S; Kadomatsu K; Sakamoto K
J Biochem; 2021 Dec; 170(5):631-637. PubMed ID: 34270745
[TBL] [Abstract][Full Text] [Related]
9. Role and targeting of anaplastic lymphoma kinase in cancer.
Della Corte CM; Viscardi G; Di Liello R; Fasano M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
Mol Cancer; 2018 Feb; 17(1):30. PubMed ID: 29455642
[TBL] [Abstract][Full Text] [Related]
10. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
11. Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
Webb TR; Slavish J; George RE; Look AT; Xue L; Jiang Q; Cui X; Rentrop WB; Morris SW
Expert Rev Anticancer Ther; 2009 Mar; 9(3):331-56. PubMed ID: 19275511
[TBL] [Abstract][Full Text] [Related]
13. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
[TBL] [Abstract][Full Text] [Related]
14. FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase.
Guan J; Umapathy G; Yamazaki Y; Wolfstetter G; Mendoza P; Pfeifer K; Mohammed A; Hugosson F; Zhang H; Hsu AW; Halenbeck R; Hallberg B; Palmer RH
Elife; 2015 Sep; 4():e09811. PubMed ID: 26418745
[TBL] [Abstract][Full Text] [Related]
15. The role of the ALK receptor in cancer biology.
Hallberg B; Palmer RH
Ann Oncol; 2016 Sep; 27 Suppl 3():iii4-iii15. PubMed ID: 27573755
[TBL] [Abstract][Full Text] [Related]
16. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
[TBL] [Abstract][Full Text] [Related]
17. Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.
Li T; Deng Y; Shi Y; Tian R; Chen Y; Zou L; Kazi JU; Rönnstrand L; Feng B; Chan SO; Chan WY; Sun J; Zhao H
Oncogene; 2018 Nov; 37(47):6180-6194. PubMed ID: 30013190
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic Lymphoma Kinase Regulates Internalization of the Dopamine D2 Receptor.
He D; Lasek AW
Mol Pharmacol; 2020 Feb; 97(2):123-131. PubMed ID: 31734646
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation.
Perez-Pinera P; Zhang W; Chang Y; Vega JA; Deuel TF
J Biol Chem; 2007 Sep; 282(39):28683-28690. PubMed ID: 17681947
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic lymphoma kinase as a therapeutic target.
Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
